145
145
funded expansion plan in place and we believe this gap will close as we start to execute on our plans.
Although building capacity is very important there has definitely been a shift in the way LP’s are being valued. With more licenses being issued and more capacity being added the investment community wants to see something different, the x factor you might say, and we have that with Satipharm. At present our Satipharm capsules are a very unique and innovative product within the industry and we are well ahead of the competition in ultimately achieving one of the first pharmaceutical grade products in this space. This I believe sets us apart from the competition.
Also, should outdoor growing be allowed, considering to date, we are the only public LP to announce plans in preparation for these changes, we feel this could have a significant impact on our overall value.
Another point to note is the value of being based in British Columbia cannot be under estimated when it comes to marketing and branding. BC Bud is already a global brand and we believe this differentiator is currently being overlooked. At present the anticipated regulations in respect to marketing and branding will be very prohibitive and being able to leverage an already well-established brand due to our location will be a significant advantage under the anticipated recreational framework.
CCIM: That’s about it and I thank you so much for your time and insight, Andreas. Is there an email or link our readers as well as prospective patients can learn more?
HVST: Thanks Spiro, appreciate your time. If anyone would like any information please reach out to Colin Clancy who looks after our investor relations at [email protected]